Compare SDOT & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDOT | CPHI |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | China |
| Employees | N/A | 231 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.1M |
| IPO Year | 2020 | N/A |
| Metric | SDOT | CPHI |
|---|---|---|
| Price | $3.18 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 999.9K | 36.1K |
| Earning Date | 03-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $467,078,000.00 | $4,052,266.00 |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $1.15 |
| 52 Week High | $35.60 | $3.18 |
| Indicator | SDOT | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 29.87 |
| Support Level | $2.83 | $1.15 |
| Resistance Level | $3.53 | $1.43 |
| Average True Range (ATR) | 0.54 | 0.10 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 30.46 | 0.00 |
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.